Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04779840 Completed - Cancer Clinical Trials

Retrospective Study on the Incidence and Management of Anemia in Oncology

RESPIRE
Start date: May 20, 2020
Phase:
Study type: Observational

The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies). Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management. Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.

NCT ID: NCT04763122 Completed - Cancer Clinical Trials

Thyroid Cancer in United Arab Emirates

Start date: September 2008
Phase:
Study type: Observational

The main objective of the study is to assess the trend of clinicopathological features and treatment modalities in patients with thyroid cancer in the largest oncology center in the United Arab Emirates (UAE).

NCT ID: NCT04749056 Completed - Cancer Clinical Trials

Electronic Psycho-oncological Adaptive Screening Program

EPAS
Start date: December 1, 2013
Phase: N/A
Study type: Interventional

Background: Psychological burden in cancer patients may worsen quality of life and even medical outcomes such as mortality. Nevertheless, many distressed patients are not recognized by the treating clinicians and left untreated even though effective psychosocial interventions exist. Existing screenings programs have multiple limitations such as the necessity of time consuming training and involvement of clincial staff, conventional screening instruments with limited diagnostic accuracy and the focusing on objective measures of distress, thereby neglecting subjective supportive care needs. Aims: To address some of the limitations outlined above, we developed an electronic psycho-oncological adaptive screening program (EPAS) which separately assesses distress and psychosocial care needs and provides immediate patient feedback with individualized recommendations about psychosocial care services. Design: Patients of the intervention are compared to a control condition. All participants are assessed at three measurement points (baseline, and at 3-months and 6-months follow-up). Outcomes: Outcomes assess aspects related to psychosocial care services, well-being and satisfaction. Recruitment: Patients are recruited within suitable health care facilities within the University Cancer Center Hamburg (UCCH) and other facilities in the competence network of the UCCH. Patients are checked for eligibility via review of the medical chart and consecutively recruited by research assistants. Duration of the study: From start of recruitment, 2 years are planned until data analysis. 1 year is planned for recruitment. Analyses: We conduct group comparisons in the study outcomes, both unconditional and condcitional (controlled for care relevant co-variates).

NCT ID: NCT04701736 Completed - Cancer Clinical Trials

A Trial to Assess the Influence of a Pictorial Medication Calendar on Medication Taking Behaviour

Start date: January 2017
Phase: N/A
Study type: Interventional

Determine if an oncology pictorial medication calendar will improve patient adherence to oncology supportive care medication regimens for adult patients receiving adjuvant or neo-adjuvant chemotherapy treatment for cancer.

NCT ID: NCT04698044 Completed - Depression Clinical Trials

Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period

Start date: May 8, 2020
Phase:
Study type: Observational

The COVID-19 pandemic has negatively affected individuals not only physiologically but also psychologically. The aim of this study is to examine the anxiety and depression status of cancer patients, individuals with non-cancer chronic diseases and healthy individuals with an online screening questionnaire during the COVID-19 pandemic period.

NCT ID: NCT04675021 Completed - Cancer Clinical Trials

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

Start date: November 13, 2020
Phase: Phase 1
Study type: Interventional

The Sponsor is developing the test medicine, AZD6094 (Savolitinib) for the potential treatment of cancer. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably, causing a growth called a tumour. The test medicine works to inhibit a pathway within the body which promotes tumours to grow and spread. The study involves radiolabelling (labelling the molecule with radioactive 14C) which is used to locate the molecule within the body. The study will evaluate the absolute bioavailability of the test medicine (amount of the oral test medicine that enters the blood stream relative to the dose given into the vein), along with the mass balance (how much radioactivity can be recovered from the urine and faeces) and the rates and routes of elimination of [14C]savolitinib. It will also look to identify the breakdown products (metabolites) of the test medicine. The safety and tolerability of the test medicine will be assessed. The study will consist of two parts, involving a minimum of eight healthy male volunteers. In Part one, following a high fat breakfast, volunteers will receive a single oral dose of the test medicine, followed by an intravenous infusion (solution into the vein) of radiolabelled test medicine. Volunteers will remain resident in the clinical unit until 72 hours post-oral dose. There will then be a washout period of at least 14 days, after which the volunteers will return to the clinical unit for Part two. Volunteers will receive a single oral dose of radiolabelled test medicine as an oral solution. Blood, urine and faecal samples will be collected from volunteers whilst they are resident in the clinical unit for up to 168 hours postdose (Day 8). Volunteers will return for a follow-up visit at least 14 days after their last dose for safety assessments.

NCT ID: NCT04663958 Completed - Cancer Clinical Trials

Predictive Value of Ariscat Index In The Development of Pulmonary Complication After Major Abdominal Cancer Surgery

Start date: November 20, 2019
Phase:
Study type: Observational

The term postoperative pulmonary complication is the development of any complications affecting the respiratory system after anesthetic and surgery procedures. The ARISCAT risk assessment score is a seven-variable regression model that divides patients into low, moderate, and high-risk groups. In this study, the investigators aimed to investigate the effectiveness of the ARISCAT risk scoring index in predicting postoperative pulmonary complication development in patients scheduled for major abdominal cancer surgery.

NCT ID: NCT04656717 Completed - Cancer Clinical Trials

Cost of Cancer Diagnosis Using Next-generation Sequencing Targeted Gene Panels in Routine Practice

Start date: March 2014
Phase:
Study type: Observational

The aim of this study was to measure the total cost of performing next-generation sequencing (NGS) in clinical practice in France, in both germline and somatic cancer genetics. The study was performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost was estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. A top-down methodology for specific post-sequencing steps was used. Additional non-specific costs were also included and costs were detailed per step of the process.

NCT ID: NCT04643613 Completed - Cancer Clinical Trials

Effect of Nutritional Formula (Protison) on Various Cancer Patients: A Randomized Clinical Trial

Protison
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Many studies (including ASPEN/ESPEN) have demonstrated that balanced diet formula rich in omega 3 fatty acids (ω-3 FA), fibers, protein as well as mineral, vitamins (trace elements) are essential for cancer patients to improve health status and tolerability of chemotherapy. Hence, the present multi-centered, randomized clinical trial was framed to evaluate the efficacy of ready to use balanced nutritional formula-PCNF (rich in ω-3 FA, fibers, MTC, BCAA, and micro-nutrients), in various cancer patient by checking calorie intake and overall health status through assessing various anthropometric and biochemical parameters especially total proteins, pre-albumin, and transferrin.

NCT ID: NCT04636346 Completed - Cancer Clinical Trials

COMPASS: A Group ACT Program for Cancer Patients Treated at UCSF

Start date: March 24, 2020
Phase:
Study type: Observational

Cancer Center Psychosocial services (Psycho-Oncology) offers group psychoeducational and behavioral programs as part of its clinical service for cancer patients and services at the Helen Diller Family Comprehensive Cancer Center. Clinical outcomes and acceptability/feasibility and implementation process data from these programs are routinely gathered in an effort to engage in continuous quality improvement for the department.